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FGF-10 plays an important role in development and disease, acting as the key ligand for FGFR2B to regulate cell
proliferation, migration and differentiation. Aberrant FGF signalling is implicated in tumourigenesis, with several
cancer studies reporting FGF-10 or FGFR2B upregulation or identifying activating mutations in Fgfr2. We used 5’
RACE to identify a novel transcription start site for murine Fgf-10. Conventional in silico analysis predicted multiple
binding sites for the transcription factor PEA3 upstream of this site. Binding was conﬁrmed by chromatin
immunopreciptation, and functional signiﬁcance was studied by both RNAi knockdown and transient over-expression
of PEA3. Knockdown of PEA3 message led to increased Fgf-10 expression, whereas overexpression of PEA3 resulted
in decreased Fgf-10 expression. Thus, we have identiﬁed PEA3 as a negative regulator of Fgf-10 expression in a murine
cell line and conﬁrmed that activity also is seen in human breast cancer cell lines (MCF-7 and MDA-MB-231).
Furthermore, over-expression of PEA3 in these cells resulted in impaired cell migration, which was rescued by
treatment with FGF-10. Thus, PEA3 can regulate the transcription of Fgf-10 and such modulation can control breast
cancer cell behaviour.
r 2009 Elsevier GmbH. Open access under CC BY license.
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Fibroblast growth factors (FGFs) comprise a family
of 22 members that play important roles during
embryogenesis and adulthood, regulating a wide range
of cellular behaviours including proliferation, migration,
survival and differentiation (Ornitz and Itoh, 2001).
Genetic studies have shown that FGF-10, a secreted
glycoprotein that acts as a paracrine signalling molecule
in many tissues (Beer et al., 1997), is crucial for009 Elsevier GmbH. Open access under CC BY license.
cb.2009.01.004
ing author. Tel.: +44207 7014 0415;
14 0431.
ess: r.p.grose@qmul.ac.uk (R. Grose).epithelial-mesenchymal interactions during development
(Min et al., 1998; Sekine et al., 1999). FGF-10 signals
through two transmembrane tyrosine kinase receptors –
FGFR1B and FGFR2B, to which it binds with low and
high afﬁnities, respectively (Zhang et al., 2006). Genetic
studies in mice have shown FGFR2B to be the key
receptor for transducing FGF-10 signalling (Celli et al.,
1998; De Moerlooze et al., 2000; Min et al., 1998; Sekine
et al., 1999).
Aberrant FGF signalling has been linked not only
with developmental abnormalities but also with
cancer. Hypomorphic Fgf-10 mutations have been
shown to cause lacrimo-auriculo-dento-digital (LADD)
syndrome-like defects in both mice and humans
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has been implicated in the development of craniosynos-
tosis (Ibrahimi et al., 2004; Wilkie et al., 2002).
Increased expression of FGF-10 has been described in
several tumours, including those of the colorectum,
prostate and breast (Matsuike et al., 2001; Memarzadeh
et al., 2007; Nomura et al., 2008; Theodorou et al.,
2004). Likewise, FGFR2B has been implicated in cancer
susceptibility and progression in a variety of ways
(Grose and Dickson, 2005; Katoh, 2008). Elevated
expression of FGFR2B has been described in breast,
colorectal, cervical, pancreatic and prostate cancers
(Kurban et al., 2004; Matsuike et al., 2001; Memarzadeh
et al., 2007; Meyer et al., 2008; Nomura et al., 2008).
Activating mutations or ampliﬁcations of Fgfr2 also
have been identiﬁed in breast, lung, stomach and
endometrial cancers (Adnane et al., 1991; Davies
et al., 2005; Jang et al., 2001; Pollock et al., 2007).
Furthermore, genome-wide single-nucleotide poly-
morphism (SNP) analyses have identiﬁed SNPs in
FGFR2 that result in increased susceptibility to breast
cancer by elevating FGFR2 expression (Easton et al.,
2007; Hunter et al., 2007; Meyer et al., 2008). However,
although FGFR2 signalling clearly plays an oncogenic
role in some cancers, in several tissues, including
bladder, skin and prostate, it also can act as a tumour
suppressor (Feng et al., 1997; Grose et al., 2007; Ricol
et al., 1999).
Polyoma enhancer activator 3 (PEA3), a member of
the PEA3 family of ETS-family transcription factors
(Sharrocks, 2001), also has been reported to play both
oncogenic and tumour-suppressive roles in cancer.
PEA3 expression has been shown to exert anti-
proliferative effects on breast and ovarian cancer cells,
and also to improve survival in mouse models of cancer
(Xing et al., 2000; Yu et al., 2006). However, there are
also many studies implicating PEA3 as a driving factor
in several neoplasms, including breast, colorectal and
lung and ovarian cancer (Benz et al., 1997; Davidson
et al., 2003; Hiroumi et al., 2001; Liu et al., 2004).
PEA3 family members are expressed at many sites of
epithelial-mesenchymal interaction during development
(Chotteau-Lelievre et al., 1997). Pea3 has been identiﬁed
as a target of FGF-10/FGFR2B signalling in the
developing lung, where its expression is induced in
distal lung bud epithelial cells in response to a
mesenchymally-derived FGF-10 signal (Liu et al.,
2003), and also in the pancreas (Kobberup et al.,
2007). Thus, although FGF-10 is known to regulate
Pea3 expression, our study is the ﬁrst to describe the
converse interaction; that is that PEA3 can regulate the
expression of Fgf-10.
Despite a previous in silico study having predicted the
transcription start site of murine Fgf-10 (Katoh and
Katoh, 2005), no experimental evidence exists to
support this location. Since FGF-10 signalling providesa powerful regulatory signal, both in development and
cancer, the aim of our present study was to identify a
deﬁnitive transcription start site for Fgf-10 in order to
investigate possible regulatory mechanisms that may
control its expression.Materials and methods
Cell culture
MDA-MB-231 and MCF-7 cells were grown in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) without
phenol red (Sigma, Poole, UK) supplemented with 10%
foetal bovine serum (FBS; Biosera, Ringmer, UK) and
4mM L-glutamine (CR-UK LRI Cell Services, Potters
Bar, UK). Immortalised mouse endothelial cells, gener-
ated from an H-2KbtsA58 transgenic mouse line (Jat
et al., 1991), were a kind gift from Dr. Gabi D’Amico
Lago and Dr. Kairbaan Hodivala-Dilke. Endothelial
cells were seeded into T75 Nunc tissue culture ﬂasks
(VWR, Lutterworth, UK) pre-coated for 1 h at 37 1C
with 0.1% gelatine (Sigma), 10 mg/ml ﬁbronectin (Sig-
ma) and 30 mg/ml collagen (type I; PureCols) (Inamed
Biomaterials, Nutacon, The Netherlands). Cells were
grown in low-glucose DMEM:Hams F-12 (1:1; CR-UK
Cell Services), supplemented with 10% FBS, 4mM
L-glutamine, 20U/ml IFN-g (Peprotech, London, UK),
0.05mg/ml endothelial mitogen (Biogenesis, Poole, UK)
and 0.01mg/ml heparin (Sigma). All cells were incu-
bated at 37 1C, 8% CO2 and 100% relative humidity.
RNA ligase-mediated rapid ampliﬁcation of cDNA
ends (RLM-RACE)
RLM-RACE was performed for the identiﬁcation of the
murine Fgf-10 transcription start site. A FirstChoices
RACE-ready cDNA kit was used according to the
manufacturer’s instructions (Ambion, Warrington, UK).
Brieﬂy, total RNA was isolated from E18.5 mouse lung
using TriReagent (Sigma) and 10mg was used for 5’ RLM-
RACE, to facilitate the cloning of the full-length Fgf-10 5’
cDNA sequence. 5’ RLM-RACE adapter sequence is given
in Table 1. Taq-ampliﬁed 5’ RLM-RACE PCR products
were cloned into pBluescript SK vector (Stratagene,
Cheshire, UK), and four clones were sequenced fully. The
putative promoter region of murine Fgf-10 (the 500bp
directly upstream of the newly identiﬁed transription start
site) was analysed in silico using the ‘Transcription Element
Search System’ (TESS) (Schug, 2003).
Nested PCR for 5’ RLM-RACE
Nested PCR was performed according to the manu-
facturer’s instructions (FirstChoices RACE-ready
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Table 1. Oligonucleotides (adapters and primers) used in this study.
Method Oligonucletotide Sequence
5’ RLM-RACE Fgf-10 adapter 5’-
GCUGAUGGCGAUGAAUGAACACUGCGUUUGCUGGCUUUGAUGAA
Nested PCR for 5’
RLM-RACE
Forward outer primer 5’-GCTGATGGCGATGAATGAACACTG
Forward inner primer 5’-CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG
Reverse inner primer 5’-CTGGGAACGCCAGCAGAAAAGGGA
Reverse outer primer 5’-GGTGGGACATCTGAAACCCT
Cloning of human
PEA3
Forward primera 5’-ATGGATCCAGGATGGAGCGGAGGATGAAA
Reverse primera 5’-CCCTCTAGACTAGTAAGAGTAGCCACCCT
RT-PCR and real-time
RT-PCR
Mouse & human
HPRTb
fwd 5’-CCTGCTGGATTACATTAAAGCACTG
rev 5’-GTCAAGGGCATATCCAACAACAAAC
Human GAPDH fwd 5’-CCATGGAGAAGGCTGGGG
rev 5’-CAAAGTTGTCATGGATGACC
Mouse Fgf-10 fwdc 5’-CGCAATTAGCAGGAGCTGCAG
rev 5’-GGTGGGACATCTGAAACCCT
Human Fgf-10 fwd 5’-ATGTCCGCTGGAGAAAGCTA
rev 5’-CCTCTCCTTGGAGCTCCTTT
Human GAPDHd fwd 5’-GACAGTCGGAAACTGGGAAG
rev 5’-GGCTGCAGGAGAAGAAAATG
Mouse Pea3 fwd 5’-AAACAGGAGCGCACAGACTT
rev 5’-GCCTGTCCAAGCAATGAAAT
Human Pea3 fwd 5’-CTGAGATCCTCTGGCACCTC
rev 5’-CTGAGTCGTAGGCGAAGTCC
Mouse Fgf-10e fwd 5’-AATTCGGAAAGCACGCGGAC
rev 5’-GGTGGGACATCTGAAACCCT
Mouse Fgf-3f fwd 5’-CTGTCTCACAGGATCACTAC
rev 5’-CTTGAAGCTGTAAAGGCATGC
aEngineered BamHI and XbaI recognition sites, respectively, are given in bold.
bexcluding genomic DNA
cwhere transcription starts
dPrimers in the promoter region
edirectly upstream of the predicted transcription start site
fgenomic DNA control primers
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transcriptase reaction was used for the outer 5’ RLM-
RACE PCR, and 1 ml from the ﬁrst PCR was used for
the subsequent inner 5’ RLM-RACE PCR. Primer
sequences are given in Table 1. Outer and inner PCRs
were performed as follows: 3min at 94 1C; 35 cycles
(94 1C for 30 s, 60 1C for 30 s, 72 1C for 30 s); 72 1C for
7min. Results were analysed by electrophoresis on a 2%
agarose/TBE gel.Chromatin immunoprecipitation (ChIP) analysis
ChIP was performed, according to the manufacturer’s
instructions (ChIP kit; Upstate Biotechnology, Dundee,
UK), to identify a possible interaction between the
transcription factor PEA3 and the Fgf-10 promoter.
Brieﬂy, immortalised mouse endothelial cells were used
as starting material, with chromatin cross-linked by
ﬁxation in 1% formaldehyde for 10min at 37 1C prior to
lysing the cells. Approximately 1 106 cells were lysed in200 ml SDS lysis buffer (Upstate Biotechnology), and the
was DNA sheared by sonication (4 10 s sonication;
6 mm amplitude with a 30-s break between each round;
Soniprep 150 MSE, Sanyo, Japan) to an average length
of approximately 500 bp. The range of DNA fragment
size was conﬁrmed by reversing the crosslinks with 8 ml
5M NaCl in 200 ml cell lysate at 65 1C for 4 h, recovering
the DNA by phenol/chlorophorm extraction and
electrophoresing the sample on a 1% agarose/TBE
gel). The sonicated cell lysate was diluted 10-fold in
ChIP dilution buffer (Upstate), and 1% of the diluted
DNA was kept as the input control for subsequent PCR
analysis. Histones were pre-cleaned with salmon sperm
DNA/protein A agarose 50% slurry for 1 h at 4 1C with
agitation. Pre-cleaned chromatin was immunoprecipi-
tated with 2 mg anti-PEA3 antibody (Santa Cruz,
Heidelberg, Germany), anti-RNA polymerase II anti-
body (positive control; Upstate Biotechnology) or IgG1
control (BD Pharmingen, Oxford, UK) per sample
overnight at 4 1C with constant rotation. The antibody/
histone complex was collected by adding salmon sperm
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volume) for 1 h at 4 1C with constant rotation. The
samples were washed and eluted according to the
manufacturer’s instructions. Both the immunoprecipi-
tated and the control input samples (each in 500 ml
volume) were then subjected to cross-link reversal. To
each sample was added; 10 ml 0.5M EDTA, 20ml 1M
Tris-HCl, pH 6.5, and 2ml of 10mg/ml proteinase K,
and samples were incubated for 1 h at 45 1C. DNA was
recovered by phenol/chloroform extraction and ethanol
precipitation. PCR was performed with Fgf-10 and
GAPDH (positive control) primers (as used above).
RNA interference
Cells (40–50% conﬂuent in 6-well plates) were
transfected for 4 h with 100 nM siRNA (Genome smart
pool for mouse Pea3 ETV4, NM_008815; D-001206-13-
05; Dharmacon, Cramlington, UK) using Oligofecta-
mine (Invitrogen, Paisley, UK). mRNA, protein level
and functional activity were assayed 24–72 h post-
transfection, and compared with mock- and/or control
siRNA-treated cells (SiControl non-targeting siRNA
pool; D-001210-02-20, Dharmacon). Transfection efﬁ-
ciency was assessed independently using a positive
control siRNA lamin A/C (D-001050-01-05, Dharma-
con) which was compared with the SiControl non-
targeting siRNA.
Cloning PEA3-encoding cDNA and transient
transfection
Forward and reverse PCR primers containing en-
gineered BamHI and XbaI recognition sites, respectively
(bold in primer sequences given in Table 1), were used to
amplify the full-length coding sequence of PEA3 from
total RNA isolated from immortalised human kerati-
nocytes (HaCaT cell line; kind gift of Prof Petra
Boukamp (Boukamp et al., 1988)). The primers were
used at an annealing temperature of 60 1C. The hPEA3
PCR product was cloned into the BamHI and XbaI sites
of the pcDNA4/TO mammalian expression vector
(Invitrogen).
MDA-MB-231 and MCF-7 cells were transfected
with 1 mg DNA using 3 ml Lipofectamine 2000 (Invitro-
gen) for 4 h. Transfection efﬁciency of both cell lines was
485%, as determined by immunoﬂuorescence imaging
following transfection with a control pcDNA4/TO-GFP
vector expressing green ﬂuorescent protein (data not
shown).
RT-PCR and real-time RT-PCR
Extraction of total RNA was performed using an
RNeasy kit (Qiagen, Crawley, UK). All samples weretreated with DNase prior to synthesis of cDNA using
Superscript IIs Reverse Transcriptase (Invitrogen). RT-
PCR was performed using Megamix Blues PCR
mastermix (Cambio, Cambridge, UK). Real-time RT-
PCR was performed using a QuantiTech SYBR Green
RT-PCR kit (Qiagen) with hypoxanthine-guanine phos-
phoribosyltransferase (HPRT) and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as housekeeping
genes for normalisation. For real-time RT-PCR the
threshold ampliﬁcation cycles were determined using a
7900HT Fast Real-Time PCR machine (Applied Bio-
systems, Warrington, UK).
The primer pair sequences are given in Table 1.
All primers were used at an annealing temperature
of 60 1C.Western blotting
Cell lysates were prepared using RIPA buffer
(Upstate Biotechnology) containing 1mM NaF, 1mg/
ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1mM
phenylmethylsulphonyl ﬂuoride (PMSF) (all Sigma) and
the protein yield was determined using a Bradford dye
binding assay (Bio-Rad, Hercules, USA). Equivalent
amounts of protein from different lysate samples (60 mg/
well) were resolved by pre-cast 4–12% NuPAGEs
Novexs Bis-Tris mini Gels (Invitrogen) gel electropho-
resis. Four primary antibodies were used: anti-alpha-
tubulin antibody (1:2000; Sigma; reactivity: mouse and
human); anti-FGF-10 antibody (1:1000; Abcam, Cam-
bridge, UK; reactivity: mouse and human); anti-PEA3
(1:500; Santa Cruz Biotechnology; reactivity: mouse,
human, rat); anti-lamin A/C antibody (0.5 mg/ml; Santa
Cruz Biotechnology; reactivity: mouse and human).
Blots were developed with ECL (GE Healthcare,
Amersham, UK). Densitometric analysis was performed
using Image-Pro Plus software (Media Cybernetics,
Bethesda, USA). Signal density was normalised to
anti-alpha-tubulin antibody as a loading control/refer-
ence, for at least three separate treatments.Migration assay
Cells (1 105) were plated onto 8 mm-pore Trans-
wells migration ﬁlters in 24-well plates (Corning, New
York, USA). PEA3- and/or empty vector-transfected
cells were used 36 h post-transfection. Cells were
incubated either in DMEM supplemented with 4mM
L-glutamine and 1–10% FBS gradient or in DMEM
supplemented with 0.1% BSA (Sigma) and with 4mM
L-glutamine without FBS overnight (12 h). Where
mentioned, recombinant FGF-10 (100 ng/ml; Peprotech,
London, UK) together with heparin (300 ng/ml; Sigma)
was added to the serum-free medium. When an FBS
gradient was used, the bottom of the Transwells
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solution (Sigma) for 1 h at room temperature prior to
plating the cells. In the absence of FBS, the bottom of
the Transwells was coated with 10 mg/ml ﬁbronectin
(Sigma) for 1 h at 37 1C prior to plating the cells. Cells
from the upper chamber, which had not migrated, were
removed with a cotton bud. Cells that had migrated to
the lower surface were trypsinised and the cell number
was determined using an automatic CASY cell counter
(Scharfe system, Leipzig, Germany).
Proliferation assay
PEA3 and/or empty vector-transfected cells (5 104)
were plated in a 24-well plate in DMEM supplemented
with 4mM L-glutamine and 10% FBS. Cells were
trypsinised and counted after 12 h using an automatic
CASY cell counter.
Data analysis
All quantitative data are presented as means7stan-
dard errors, unless stated otherwise. Statistical signiﬁ-
cance was determined with Student’s t-test or Mann-
Whitney Rank Sum test as appropriate. When multiple
conditions were compared, one way analysis of variance
(ANOVA) followed by Newman-Keuls test was per-
formed. Real-time PCR data were analysed using the
2DDCt method (Livak and Schmittgen, 2001). Results
were considered signiﬁcant at Po0.05 (*). Unless
otherwise stated, all experiments were performed in
triplicate as a minimum.Results
Identiﬁcation of a novel Fgf-10 transcription start
site
Previous studies have predicted the Fgf-10 transcrip-
tional start site (Katoh and Katoh, 2005), but unequi-
vocal experimental evidence for this activity was lacking.
Using total RNA from E18.5 mouse lung tissue, we
performed 5’ RLM-RACE in order to identify the Fgf-
10 transcription start site. Subsequently, nested PCR
was performed with speciﬁc forward primers for the 5’
RLM-RACE adaptor and reverse primers from a
known sequence of the Fgf-10 gene (data not shown).
Taq-ampliﬁed 5’ RLM-RACE PCR products were
cloned and four independent clones were sequenced
(Fig. 1B). Here we report that we have identiﬁed a novel
Fgf-10 transcription start site, located 251 bp upstream
of that predicted in silico, 653 bp upstream of the
published Entrez site and 1001 bp upstream of the
translation start site (Fig. 1A). Our results wereconﬁrmed by RT-PCR using a forward primer from
over the newly identiﬁed transcription start which
ampliﬁed a band both with cDNA generated from
E18.5 mouse lung and with positive control genomic
DNA (gDNA) (Fig. 1B). In contrast, RT-PCR using a
forward primer recognising the 20 base pairs directly
upstream of the predicted transcription start site
ampliﬁed a band only with the positive control (gDNA)
and not with the cDNA. Control primers, speciﬁc to an
intronic sequence, conﬁrmed the absence of genomic
DNA contamination in the cDNA sample, while control
primers, speciﬁc for a cDNA sequence known to be
expressed (the housekeeping gene, HPRT), gave a
strongly positive band. Thus, these data support our 5’
RLM-RACE results, suggesting a novel start site for
Fgf-10 transcription 1001 bp upstream of the translation
start site.PEA3 binds to the Fgf-10 promotor region
We then analysed the immediate upstream region of
Fgf-10 using an on-line Transcription Element Search
System (TESS). Analysis revealed a region of approxi-
mately 120 bp in the newly deﬁned promoter region
containing 12 copies of the consensus binding sequence
for PEA3 (AGGAA). This string of sites was not
conserved in the human Fgf-10 promoter, however,
there were several PEA3 recognition sites within the
region. Interestingly, 8 PEA3-binding sites also were
present in the human (NC_000005.8) Fgf-10 promoter
region in conserved positions.
To conﬁrm interaction of PEA3 with the Fgf-10
promotor region, we performed ChIP experiments using
immortalised mouse lung endothelial cells. RT-PCR
analysis with appropriate controls conﬁrmed that these
cells expressed both FGF-10- and PEA3-encoding
mRNA (Fig. 2A). Importantly, these cells expressed
readily detectable PEA3 protein (Fig. 2B). An antibody
to RNA polymerase II was used as a positive control for
ChIP, with speciﬁc DNA binding conﬁrmed by PCR
with GAPDH primers. As expected, only the sample
immunoprecipitated using anti-RNA polymerase II
antibody yielded a PCR product (Fig. 2C, top panel).
When chromatin was immunoprecipitated with anti-
bodies to PEA3 or RNA polymerase II, Fgf-10 sequence
was detected by PCR (Fig. 2C, bottom panel).
Importantly, the negative controls, where the same
ChIP protocol was followed either with IgG or no
antibody, gave no PCR products, suggesting that our
ChIP results were a result of speciﬁc binding of RNA
polymerase II to GAPDH and PEA3 and RNA
polymerase II to Fgf-10, respectively. Thus, our ChIP
results conﬁrmed the binding of PEA3 to the endoge-
nous Fgf-10 promoter region.
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(A) RLM-RACE predicted transcription start site
(D)ATG FGF-10 translation start site
(E)End of exon1
251(B) 653(C)1(A)
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Approx.  80 kb Approx.  80 kb
Exon 2 Exon 3Exon1
Fgf-10 5′UTR
Fgf-10 coding region
PEA3-binding sites
PCR primers
gDNAcontrol
cDNAcontrol
Fgf-10 (      )
Fgf-10 (      )
cD
NA
gD
NA
Bl
an
k
GCTGATGGCGATGAATGAA
CACTGCGTTTGCTGGCTTT
AATGAAAAATTAGCAGGAG
TTGCAGGCTGCGGGGCGG
CTGCGCCCACGGAGGCGG
CGAGGAAGGGACCCGCAG
CCCCCAGCTCAGAGCAAA
GGCA…
5′-RACE Adapter
FGF-10 cDNA
KEY
Fig. 1. 5’ Genomic organisation of Fgf-10. A novel Fgf-10 transcription start site 653 nucleotides 5’ to the Entrez published site was
identiﬁed by RLM-RACE using total RNA isolated from embryonic day 18.5 mouse lung (A). Analysis of the potential promoter
region of Fgf-10 (500 to +1bp) identiﬁed a string of 12 PEA3-binding sites approximately 360 to 240 bp upstream of the novel
start site. The novel FGF-10 cDNA was conﬁrmed by PCR analysis of cDNA and genomic (gDNA) samples (from E18.5 mouse
lung) using forward primers speciﬁc to the genomic sequence immediately upstream of the predicted start site (grey) and at the
predicted start of exon 1 (black), together with a common reverse primer (black) (B). PCR products of the expected size were
obtained from both cDNA and gDNA samples when using the inner primer pair, conﬁrming the predicted Fgf-10 start site was
transcribed. The gDNA primer set yielded no product with the cDNA sample, as predicted, but ampliﬁed a clear band in the gDNA
sample. Primers speciﬁc for cDNA (housekeeping gene hPRT, with primers spanning an intron to prevent ampliﬁcation of gDNA)
and gDNA (known intron sequence from Fgf-3) conﬁrmed the integrity of both DNA samples and the lack of gDNA
contamination.
A.-M. Chioni, R. Grose / European Journal of Cell Biology 88 (2009) 371–384376PEA3 negatively regulates Fgf-10 expression
To determine the role for PEA3 in the regulation of
Fgf-10 expression, we used both RNAi-mediated knock-
down and recombinant overexpression approaches, with
subsequent real-time RT-PCR analysis. Transfection of
immortalised mouse lung endothelial cells with a pool of
RNAi oligos targeted speciﬁcally to PEA3 reduced the
level of PEA3-encoding mRNA expression by 65% and
57%, after 24 h and 48 h, respectively, when compared
to a scrambled RNAi control (Fig. 3A). By 48 h post-
RNAi treatment, Western blotting of whole cell extracts
showed PEA3 protein levels to be decreased by 34%
(Fig. 3B). However, by 72 h post-treatment the PEA3
protein levels in RNAi-treated cells had returned to
control levels (data not shown). Interestingly, although
FGF-10 mRNA levels had not changed by 24 h post-
RNAi treatment, after 48 h the level of FGF-10 mRNA
in RNAi-treated cells was 260% higher than that of
control cells (Fig. 3C). Thus, RNAi-mediated knock-down of PEA3 resulted in upregulation of FGF-10
mRNA levels, implying that PEA3 may play a negative
role in the regulation of Fgf-10 expression.
Having shown that reducing PEA3 levels led to an
increase in Fgf-10 expression, we determined whether
the converse also was true. Since FGF-10 upregulation
has been implicated in breast cancer (Theodorou et al.,
2004), we used MDA-MB-231 and MCF-7 breast cancer
cell lines as models in which to overexpress recombinant
PEA3. Both cell lines expressed FGF-10 mRNA and
protein as well as PEA3 mRNA, but not PEA3 protein
(Supplementary Fig. 1 and data not shown). This
ﬁnding was consistent with a previous study that
reported, in a number of breast cancer cell lines
including MDA-MB-231 and MCF-7 cells, PEA3
protein was not detectable (Baert et al., 1997).
Firstly, we cloned the full-length human PEA3-
encoding cDNA sequence into a mammalian expression
vector, pcDNA4/TO, and conﬁrmed orientation and
ﬁdelity by sequencing the whole insert (data not shown).
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Fig. 2. PEA3 binds to the Fgf-10 promoter region. RT-PCR
showed that immortalised murine lung endothelial cells
expressed both Fgf-10 and Pea3 (primers as in Fig. 1 for
Fgf-10 and the cDNA and gDNA controls). Pea3 primers were
designed ﬂanking an intron such that they ampliﬁed only
cDNA (A). Western blotting of 60 mg whole-cell lysate from
the same cell line showed a clear band at 70 kDa, correspond-
ing to PEA3 (B). ChIP analysis using the same anti-PEA3
antibody showed that PEA3 binds to the Fgf-10 promoter
region (C). Immunoprecipitation with an antibody to RNA
polymerase II followed by PCR using primers for GAPDH was
used as a positive control for the ChIP assay (upper panel),
with IgG and no antibody conditions used as negative
controls. Presence and integrity of the ChIP input DNA was
conﬁrmed by PCR, using genomic DNA puriﬁed from ES cells
as a positive control for primer efﬁciency. ChIP analysis using
primers speciﬁc for Fgf-10 yielded a speciﬁc PCR product both
with the anti-RNA polymerase II immunoprecipitate and,
more strongly, with the anti-PEA3 immunoprecipitate.
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expression construct, real-time RT-PCR revealed that
levels of PEA3 mRNA expression in MDA-MB-231
cells increased by over 3000-fold compared to the
negligible levels seen in cells transfected with empty
pcDNA4/TO vector (Fig. 4A). Similarly, PEA3 protein
was detected readily in PEA3-transfected MDA-MB-
231 cells, but not in empty vector control cells (Fig. 4B).
Crucially, at the same 48 h timepoint, PEA3-transfected
cells showed a 73% reduction in FGF-10 mRNA
expression relative to controls (Fig. 4A). Similar results
were obtained at the protein level, with FGF-10 protein
reduced by 70% (Fig. 4B). Thus, over-expression of
PEA3 in MDA-MB-231 cells decreased Fgf-10 expres-
sion. Similar results were obtained with MCF-7 cells(data not shown). These results are consistent with the
RNAi-mediated knockdown of PEA3 in mouse lung
endothelial cells, suggesting that PEA3 is a negative
regulator of Fgf-10 expression.
All real-time PCR results were performed using two
different housekeeping genes (HPRT and GAPDH)
as controls. The data presented were normalised to
HPRT mRNA levels, however the results were the same
when GAPDH was used for normalisation (Data not
shown).Over-expression of PEA3 in breast cancer cells
decreases cell migration
In order to investigate whether PEA3 over-expression
had any functional effect on breast cancer cells, we
performed Transwells migration assays (Fig. 5A). Cells
were allowed to migrate in the absence of FBS, since
FBS contains a number of potential growth factors that
might inﬂuence cell migration. The bottom of the
Transwells membrane was coated with ﬁbronectin,
allowing cells migrating through the membrane to
adhere to the lower surface. Interestingly, over-expres-
sion of PEA3 decreased cell migration to 62% of control
levels in MDA-MB-231 cells and to 65% in MCF-7 cells
(Fig. 5A). Identical results were obtained when cells
were allowed to migrate in the presence of a 1–10% FBS
gradient (Supplementary Fig. 2). To determine whether
the inhibitory effect of PEA3 was dependent on FGF-
10, we added recombinant FGF-10 (100 ng/ml) to the
medium of cells transfected with a PEA3 expression
construct and empty vector controls, resulting in a
rescue in the migratory capacity of PEA3-expressing
cells to control levels (Fig. 5A). Given that one major
outcome of FGF-10 signalling is mitosis (Ornitz and
Itoh, 2001), we conﬁrmed that differences in cell
proliferation did not inﬂuence our migration data. Cells
in all experimental groups showed no differences in
proliferation over the same timeframe that was used for
our migration experiment, as expected for an assay
conducted in serum-free conditions over a 12-h period
(Fig. 5B). Thus, we have shown a signiﬁcant inhibitory
effect of PEA3 expression on cell migration and
demonstrated that this reduction in migration is rescued
by treatment with exogenous FGF-10.
Taken together, our results identify a novel transcrip-
tion start site for Fgf-10 and show that the transcription
factor PEA3 binds upstream of this site. We go on to
provide functional evidence for a role of PEA3 in
negatively regulating Fgf-10 expression, supported by
RNAi knockdown, over-expression and recombinant
rescue studies. From the present study, we show that
PEA3 can exert an important inhibitory effect on cell
migration, acting at least in part via FGF-10.
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Despite apparently modest levels of expression,
the FGF-10–FGFR2B signalling axis plays a critical
role in controlling cell proliferation, apoptosis, cytopro-
tection and migration during embryogenesis and
tissue repair (Braun et al., 2004; De Moerlooze
et al., 2000; Min et al., 1998; Sekine et al., 1999).Therefore, although there are several studies reporting a
tumour-suppressive effect of FGFR2 in a variety of
cancer types, including bladder, prostate and skin
(Feng et al., 1997; Grose and Dickson, 2005; Grose
et al., 2007; Ricol et al., 1999; Zhang et al., 2001), it is
easy to see how the pathway might be hijacked by cancer
cells to provide them with a signiﬁcant growth
advantage.
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and cancer is somewhat equivocal. Our study has shown
that PEA3 overexpression in MDA-MB-231 cells
decreased cell migration, and it previously has been
shown that PEA3 can decrease invasion in a cervical
cancer cell line (Iwasaki et al., 2004). However, the role
of PEA3 in metastatic cell behaviour and cancer
prognosis is contradictory. In breast cancer, PEA3 has
been reported to act as a tumour suppressor gene by
downregulating HER-2/neu over-expression (Xing
et al., 2000). However, it also has been reported that
PEA3 can play a positive role in HER2-mediated breast
cancer progression (Myers et al., 2006) and that it can
function as an oncogene through up-regulation of
MMPs both in breast and ovarian cancer (Barrett et al.,
2002; Bieche et al., 2004; Cowden Dahl et al., 2007).
Before examining regulatory elements in a gene
promoter region, it clearly is essential to know thelocation of the true transcriptional start site. Therefore,
we have identiﬁed a novel Fgf-10 transcription start site
and show that Fgf-10 transcription is regulated by
PEA3. The genomic sequence upstream of this tran-
scription start site does not contain a canonical TATA
box, however it is within a well-deﬁned GC-rich region.
The requirement for a TATA box is thought to have
been overestimated since a large number of mammalian
genes lack such a sequence, yet can direct accurate
transcription using initiator and other downstream core
promotor elements (Butler and Kadonaga, 2002; Gross
and Oelgeschlager, 2006). Our study does not prove that
this is the only transcriptional start site for Fgf-10, but it
does show a novel regulatory mechanism for controlling
Fgf-10 expression. We provide clear evidence that, at
least in the two breast cancer cell lines that we have used
in this current study, over-expression of PEA3 has a
negative inﬂuence on Fgf-10 expression, consistent with
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suggesting that PEA3 appears to act as a negative
regulator of Fgf-10 expression. Given the complexity of
the literature regarding tumourigenic or tumour-sup-
pressive effects of PEA3 and FGFR2B, it is possible that
these effects may be cell-context dependent but the
results from all the three cell lines that we have used
all concur with PEA3 negatively regulating Fgf-10
expression.
Both assay conditions that we employed to analyse
cell migration, either in response to an FBS gradient or
in serum-free conditions, showed that over-expression of
PEA3 resulted in signiﬁcant reduction in cell migration.
The two assays have different merits. The FBS gradient
allowed cells to migrate in a relatively undeﬁned, but
perhaps more physiologically representative, environ-
ment of various mitogenic and motogenic stimuli.
Conversely, the more deﬁned serum-free conditions
were useful in determining the effect of PEA3 expressionin a relatively unstimulated cell population. Regardless
of their individual beneﬁts, both assay formats gave
essentially identical results. The migration assays were
conducted over a relatively short timeframe of 12 h,
where cell proliferation did not differ between empty
vector- and PEA3-transfected cells, with or without
exogenous FGF-10 treatment.
In the present study, we speculate that the inhibitory
role of PEA3 on breast cancer cell migration could be
due to the reduction of Fgf-10 expression by negative
regulation through PEA3. Of course, expression of
genes other than Fgf-10 will be affected by increased
expression of PEA3, potentially including MMPs,
uPAR and Cox-2 (Fuchs and Allgayer, 2003; Howe et
al., 2001), several of which might affect cell migration.
However, the rescue of the defective migration of PEA3-
expressing cells by treatment with exogenous FGF-10
suggests that PEA3 acts via FGF-10. It is beyond the
scope of this study to identify all the potential molecular
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on the migration of MDA-MB-231 and MCF-7 cells.
The novel relationship between PEA3 and FGF-10 is
interesting in light of previous ﬁndings that FGF-10
signalling can positively regulate Pea3 expression during
development in the mouse (Kobberup et al., 2007; Liu et
al., 2003), and suggests a possible mechanism for
preventing establishment of an autocrine FGF-10
positive feedback loop in cells that receive an FGF-10
signal (Fig. 6). In breast cancer cells, the lack of PEA3
could result in exactly such an autocrine situation. Thus
our data suggest that the negative effect of PEA3 on cell
migration in breast cancer cells warrants further
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